Cytek Biosciences (CTKB)
NASDAQ:CTKB
Want to see CTKB full AI Analyst Report?
Top Page
Cytek Biosciences
(NASDAQ:CTKB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.50
▼(-2.39% Downside)
Action:ReiteratedDate:05/09/26
The score is primarily held back by weak financial performance: sizeable losses, margin compression, and renewed cash burn despite strong revenue growth and low leverage. The earnings call adds modest support via reaffirmed 2026 guidance and a stated path to positive adjusted EBITDA, but near-term expense and litigation pressures temper confidence. Technicals are neutral-to-slightly constructive, while valuation lacks earnings or dividend support due to the negative P/E.
Positive Factors
Recurring revenue mix
A 35% recurring revenue share growing 19% YoY materially increases revenue predictability and reduces dependence on lumpy instrument sales. Durable reagent/service tails support higher lifetime customer value, steadier margins over cycles, and a platform for cross-selling software and services.
Negative Factors
Profitability deterioration
A reversion to large net losses and sharply negative margins indicates the current business model isn't converting top-line growth into durable profits. Sustained negative returns undermine reinvestment capacity and require either structural cost reduction or pricing/mix improvements to restore healthy unit economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue mix
A 35% recurring revenue share growing 19% YoY materially increases revenue predictability and reduces dependence on lumpy instrument sales. Durable reagent/service tails support higher lifetime customer value, steadier margins over cycles, and a platform for cross-selling software and services.
Read all positive factors
Cytek Biosciences (CTKB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$595.35M
Dividend YieldN/A
Average Volume (3M)651.21K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue Growth3.61%
EPS Growth-568.29%
CountryUS
Employees663
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.57
Shares Outstanding129,142,600
10 Day Avg. Volume496,865
30 Day Avg. Volume651,214
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit5.15
Enterprise Value/Ebitda-23.13
Forecast
1Y Price Target
$6.25Price Target Upside35.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$208.12M
Cytek Biosciences Business Overview & Revenue Model
Company Description
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow c...
How the Company Makes Money
Cytek makes money primarily by selling flow cytometry instruments and then generating recurring follow-on revenue from the installed base through consumables and services. Key revenue streams typically include: (1) Instrument sales: upfront revenu...
Cytek Biosciences Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call presented a mix of constructive commercial momentum—led by a strong U.S. rebound, double-digit growth in recurring revenue, robust installed base expansion and growing cloud/user engagement—while also disclosing near-term profitability pressures from higher operating and legal expenses, regional disruption (EMEA) and APAC order timing. Management reaffirmed full-year guidance and expects adjusted EBITDA to turn positive for 2026, supported by a strong balance sheet.Positive Updates
Revenue Growth and Constructive Start to 2026
Q1 2026 revenue was $44.1M, up 6% year-over-year from $41.5M, representing a constructive start to the year and management's view of a return to more normal U.S. market conditions.
Negative Updates
Regional Headwinds in EMEA
EMEA revenue declined 7% year-over-year to $10.8M; management attributed softness to disruption from the conflict in the Middle East and an end-of-quarter shipment delay in another region.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Constructive Start to 2026
Q1 2026 revenue was $44.1M, up 6% year-over-year from $41.5M, representing a constructive start to the year and management's view of a return to more normal U.S. market conditions.
Read all positive updates
Company Guidance
Cytek reaffirmed full‑year 2026 revenue guidance of $205–$212 million (about 2%–5% growth year‑over‑year) assuming no change in currency rates, saying the outlook rests on continued growth in services and reagents at recent levels, flat‑to‑modest instrument growth and a contingency for macro risks; Q1 metrics cited include GAAP gross margin of 48% (adjusted gross margin 51%), an adjusted EBITDA loss of $9.1M (management expects adjusted EBITDA to improve each quarter and to be positive for full‑year 2026), trailing‑12‑month recurring revenue of $18.4M (35% of total, +19% YoY), and cash and marketable securities of $262.2M as of March 31, 2026, with the company forecasting gross margins to increase as revenue builds seasonally.Cytek Biosciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 204.17M | 201.49M | 200.45M | 193.01M | 164.04M | 127.95M |
| Gross Profit | 105.56M | 104.46M | 111.11M | 109.43M | 100.97M | 79.14M |
| EBITDA | -23.50M | -17.39M | -10.03M | -4.41M | 9.49M | 8.92M |
| Net Income | -74.00M | -66.54M | -6.02M | -12.15M | 2.58M | 3.00M |
Balance Sheet | ||||||
| Total Assets | 449.11M | 461.54M | 499.50M | 494.46M | 519.48M | 463.31M |
| Cash, Cash Equivalents and Short-Term Investments | 262.23M | 261.53M | 277.86M | 262.41M | 341.15M | 364.62M |
| Total Debt | 13.83M | 23.74M | 17.02M | 14.14M | 18.09M | 0.00 |
| Total Liabilities | 121.47M | 119.80M | 103.76M | 101.39M | 93.93M | 57.92M |
| Stockholders Equity | 327.64M | 341.74M | 395.74M | 393.06M | 425.30M | 405.04M |
Cash Flow | ||||||
| Free Cash Flow | -12.70M | -8.77M | 21.85M | 454.00K | -22.10M | 266.00K |
| Operating Cash Flow | -7.30M | -4.69M | 25.38M | 5.28M | -12.23M | 4.63M |
| Investing Cash Flow | -26.41M | 10.12M | -82.97M | -93.89M | -55.91M | -20.99M |
| Financing Cash Flow | 2.09M | -13.43M | -15.82M | -41.81M | 5.51M | 213.56M |
Cytek Biosciences Technical Analysis
Positive
4.61
Price Trends
4.41
Positive
4.82
Negative
4.38
Positive
Market Momentum
0.05
Negative
54.43
Neutral
50.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Positive. The current price of 4.61 is above the 20-day moving average (MA) of 4.55, above the 50-day MA of 4.41, and above the 200-day MA of 4.38, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 54.43 is Neutral, neither overbought nor oversold. The STOCH value of 50.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTKB.
Cytek Biosciences Risk Analysis
Cytek Biosciences disclosed 64 risk factors in its most recent earnings report. Cytek Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Issues in the development and use of artificial intelligence technologies, combined with an uncertain regulatory environment, may result in reputation harm, liability, or other adverse consequences to our business operations. Q4, 2025
2.
Disruptions at the FDA, the SEC, and other government agencies and regulatory authorities from funding cuts, personnel losses, regulatory reform, government shutdowns, and other developments could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. Q4, 2025
3.
regulations, which can be expensive and restrict how we do business, and could expose us to liability if our use of such hazardous materials cause injury. Q4, 2025
Cytek Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $875.96M | 48.32 | 16.27% | ― | 1.52% | ― | |
56 Neutral | $542.87M | -130.15 | -11.00% | ― | 20.19% | 40.88% | |
52 Neutral | $1.09B | -20.44 | -36.79% | ― | 20.20% | -0.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $595.35M | -7.45 | -18.01% | ― | 3.61% | -568.29% | |
47 Neutral | $413.84M | -13.58 | -17.61% | ― | 3.63% | -93.57% | |
45 Neutral | $425.82M | -12.20 | -488.45% | ― | 5.04% | 81.29% |
* Healthcare Sector Average
CTKB
Cytek Biosciences
4.61
1.59
52.65%
PACB
Pacific Biosciences
1.41
0.31
28.18%
VREX
Varex Imaging
9.83
2.31
30.72%
SIBN
SI-Bone
12.27
-6.51
-34.66%
BFLY
Butterfly Network
4.16
1.81
77.02%
BVS
Bioventus
10.50
3.76
55.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.